3056822-31-9
Chemical Structure
Pep-20
- CAS No.: 3056822-31-9
- Formula:C74H93N21O18
- Molecular Weight:1564.66
InChIKey: HASMJIJXAAVERB-OFJXVRAUSA-N
SMILES: O=C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CO)C(N[C@@H](CC(N)=O)C(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H](CC6=CNC7=CC=CC=C67)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC8=CNC=N8)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C)N
Biological Activity: Pep-20 is a CD47 binder with a human Kd of 2.91 µM and a murine Kd of 3.63 µM. Pep-20 blocks the interaction between CD47 and SIRPα, with an IC50 of 24.56 µM for human targets and 12.03 µM for murine targets. Pep-20 also acts as a phagocytosis enhancer and an inducer of anti-tumor immune responses. By blocking the CD47/SIRPα interaction, Pep-20 reduces the tyrosine phosphorylation level of SIRPα, disrupts the inhibitory "don't eat me" signaling pathway, enhances macrophage-mediated phagocytosis of solid tumor cells and hematologic tumor cells, and promotes macrophage mobilization of anti-tumor T-cell responses. Pep-20 can be used in research related to solid tumors, hematologic malignancies, breast cancer, and pancreatic cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pep-20 | 99.94% | Pep-20 is a CD47 binder with a human Kd of 2.91 µM and a murine Kd of 3.63 µM. Pep-20 blocks the interaction between CD47 and SIRPα, with an IC50 of 24.56 µM for human targets and 12.03 µM for murine targets. Pep-20 also acts as a phagocytosis enhancer and an inducer of anti-tumor immune responses. By blocking the CD47/SIRPα interaction, Pep-20 reduces the tyrosine phosphorylation level of SIRPα, disrupts the inhibitory "don't eat me" signaling pathway, enhances macrophage-mediated phagocytosis of solid tumor cells and hematologic tumor cells, and promotes macrophage mobilization of anti-tumor T-cell responses. Pep-20 can be used in research related to solid tumors, hematologic malignancies, breast cancer, and pancreatic cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang H, et al. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy. Journal for immunotherapy of cancer. 2020 Oct;8(2):e000905. [Content Brief]
- [2]. Zhang W, et al. An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses. Nature communications. 2024 Jul 06;15(1):5670. [Content Brief]
